• Adia Med posted a net loss of USD 122,107 for the six months ended June 30, 2026, narrowing from USD 240,216.
• Revenue climbed to USD 661,660, more than doubled from USD 189,910, led by USD 434,670 from medical procedures.
• Gross profit rose to USD 350,157 from USD 39,975 as cost of revenue increased to USD 311,503 from USD 149,935.
• Operating expenses increased to USD 450,248 from USD 267,105, driven by higher legal and professional fees of USD 160,731.
• Management flagged substantial doubt about going concern, citing a USD 16,095,589 accumulated deficit despite a quarterly swing to net income of USD 40,418.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adia Med Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-006313), on August 13, 2026, and is solely responsible for the information contained therein.